All Graft versus Host Disease (GvHD) articles
-
ArticleHope for ALS and inflammatory diseases: Cellenkos' CRANE technology breakthrough
Cellenkos' CRANE technology, led by Dr Simrit Parmar, harnesses regulatory T cells to precisely target and treat inflammatory diseases. This innovative approach offers hope for conditions like aplastic anaemia, myelofibrosis, and ALS.
-
NewsNewly identified cell type could be key to preventing graft versus host disease
UW researchers at the Carbone Cancer Center have identified the cells that can cause graft versus host disease, the most common complication of bone marrow transplants.